about
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis.Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States.Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial
P2860
Q30279214-418B98E8-70FF-4912-AE31-7B1E5C29CB22Q34758029-C67E427B-72DB-4298-88F9-B41648450461Q36394528-AD8F5E28-034A-4643-8CE9-963895B33A6AQ36825057-62941D78-3D7B-46F9-94AE-DBE879AB7D14Q38162941-37634C16-9CBE-4B57-9CA4-440E9C0D7C5EQ38243024-EF4BFC2B-65F6-4D85-A058-81155FFAB68DQ38289267-51BBA77E-2678-4A0B-AF46-6CBAA43ED938Q41058601-FCEAEC9F-2EE0-4739-8699-7B75404120AD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical overview of the seizure risk of dalfampridine.
@en
type
label
Clinical overview of the seizure risk of dalfampridine.
@en
prefLabel
Clinical overview of the seizure risk of dalfampridine.
@en
P2093
P2860
P1476
Clinical overview of the seizure risk of dalfampridine.
@en
P2093
Aaron Miller
E Jay Bienen
Sheryl R Haut
P2860
P304
P356
10.1517/14740338.2012.697896
P407
P577
2012-06-18T00:00:00Z